stockrow
Friday 6 November 2026
Export BSX’s income statement to Excel — free account
Boston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.
- Revenue
- +1.44%
- EPS
- −21.5%
- Free cash flow
- −25.3%
- Total debt
- +3.04%
Quarter to September 2026, against a year earlier
42.73
1.91
−4.28%
Follow BSX
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
84.15 | 316.00 | 29.21 | 13.38 | 0.00 | 61.57 | 102.24 | 54.06 | 70.89 | 48.65 |
Piotroski F-Score |
7 | 6 | 6 | 4 | 4 | 7 | 7 | 7 | 6 | 7 |
P/S ratio |
3.54 | 3.83 | 4.97 | 5.86 | 5.14 | 5.08 | 5.19 | 5.90 | 7.85 | 7.03 |
Altman Z-Score |
1.41 | 1.66 | 2.56 | 2.67 | 2.30 | 2.83 | 3.26 | 3.94 | 5.29 | 5.41 |
P/FCF ratio |
35.57 | 31.29 | 6,100.57 | 45.53 | 44.52 | 45.43 | 69.28 | 46.90 | 49.69 | 38.59 |
Altman Z″-Score (non-manufacturers) |
(0.88) | (1.00) | (0.24) | 0.93 | 1.41 | 1.64 | 1.90 | 2.13 | 2.08 | 2.81 |
Beneish M-Score |
(2.59) | (2.77) | (2.12) | (1.87) | (2.87) | (2.44) | (2.46) | (2.48) | (2.53) | (2.49) |
P/Operating CF |
43.94 | 50.64 | 2,568.66 | 90.93 | 75.68 | 126.40 | 81.56 | 87.82 | 90.27 | 103.49 |
P/B ratio |
4.41 | 4.94 | 5.59 | 4.53 | 3.32 | 3.63 | 3.75 | 4.30 | 5.97 | 5.77 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
4.17 | 4.43 | 5.67 | 6.77 | 5.89 | 5.68 | 5.82 | 6.48 | 8.47 | 7.50 |
EV/EBITDA |
78.28 | 31.18 | 37.00 | 47.93 | 36.99 | 25.39 | 25.33 | 25.65 | 33.28 | 29.97 |
EV/Operating CF |
29.60 | 28.10 | 179.72 | 39.60 | 38.69 | 36.13 | 48.38 | 36.87 | 41.27 | 33.22 |
EV/FCF |
41.91 | 36.19 | 6,964.32 | 52.62 | 51.00 | 50.80 | 77.71 | 51.49 | 53.60 | 41.18 |
Quick Ratio |
0.47 | 0.31 | 0.33 | 0.42 | 0.89 | 0.87 | 0.76 | 0.63 | 0.46 | 0.90 |
Current Ratio |
0.90 | 0.68 | 0.76 | 0.97 | 1.82 | 1.48 | 1.51 | 1.32 | 1.08 | 1.62 |
Net Debt/EBITDA |
4.15 | 2.54 | 2.84 | 3.72 | 4.70 | 2.68 | 2.75 | 2.29 | 2.43 | 1.88 |
Debt/Assets |
30.31% | 29.49% | 33.60% | 32.74% | 29.71% | 28.13% | 27.52% | 25.91% | 27.28% | 26.19% |
Debt/Equity |
0.81 | 0.80 | 0.81 | 0.72 | 0.60 | 0.55 | 0.51 | 0.47 | 0.49 | 0.47 |
Asset Turnover |
0.46 | 0.49 | 0.49 | 0.42 | 0.32 | 0.38 | 0.39 | 0.42 | 0.45 | 0.48 |
Operating CF/Net income |
3.41 | 13.71 | 0.19 | 0.39 | (13.11) | 1.90 | 2.38 | 1.59 | 1.85 | 1.56 |
Capex/Depreciation |
(0.42) | (0.38) | (0.33) | (0.41) | (0.22) | (0.37) | (0.45) | (0.57) | (0.48) | (0.62) |
Interest Coverage |
1.92 | 5.61 | 6.25 | 3.21 | (0.22) | 3.51 | 3.50 | 8.84 | 8.54 | 10.35 |
| 5.32% | 1.51% | 21.24% | 41.59% | (0.79%) | 6.17% | 3.75% | 8.46% | 8.92% | 12.47% | |
| 1.92% | 0.56% | 8.35% | 18.23% | (0.37%) | 3.13% | 1.98% | 4.64% | 4.97% | 6.98% | |
ROIC |
2.32% | 6.46% | 6.02% | 4.01% | (0.22%) | 3.15% | 4.02% | 5.27% | 5.04% | 6.65% |
Return on Tangible Assets |
27.07% | (77.04%) | 318.29% | 245.82% | (2.26%) | 22.93% | 14.58% | 35.36% | 48.57% | 39.21% |
Average Days of Receivables |
64.07 | 62.45 | 59.75 | 62.15 | 56.37 | 54.59 | 56.70 | 57.11 | 55.75 | 53.20 |
Research and Development Expense of Revenue |
10.97% | 11.02% | 11.33% | 10.94% | 11.53% | 10.13% | 10.43% | 9.93% | 9.64% | 10.22% |
Selling, General and Administrative Expense of Revenue |
37.90% | 37.16% | 37.05% | 37.32% | 38.66% | 37.08% | 36.01% | 36.77% | 35.93% | 34.54% |
Intangible Assets out of Total Assets |
0.69 | 0.67 | 0.68 | 0.59 | 0.52 | 0.56 | 0.58 | 0.58 | 0.60 | 0.58 |
Share Based Compensation of Revenue |
1.38% | 1.40% | 1.43% | 1.46% | 1.71% | 1.63% | 1.73% | 1.64% | 1.59% | 1.49% |
Graham Net Nets |
(0.27) | (0.24) | (0.17) | (0.19) | (0.17) | (0.15) | (0.14) | (0.11) | (0.08) | (0.07) |
Graham Number |
5.39 | 3.03 | 13.12 | 27.54 | 0.00 | 13.47 | 11.15 | 17.99 | 20.59 | 27.00 |
Earnings Yield |
1.19% | 0.32% | 3.42% | 7.47% | (0.34%) | 1.62% | 0.98% | 1.85% | 1.41% | 2.06% |
Free Cash Flow Yield |
2.81% | 3.20% | 0.02% | 2.20% | 2.25% | 2.20% | 1.44% | 2.13% | 2.01% | 2.59% |
Revenue per Share |
6.18 | 6.60 | 7.11 | 7.71 | 7.00 | 8.36 | 8.87 | 9.80 | 11.38 | 13.56 |
Operating CF per Share |
0.87 | 1.04 | 0.22 | 1.32 | 1.06 | 1.31 | 1.07 | 1.72 | 2.33 | 3.06 |
Capex per Share |
(0.26) | (0.23) | (0.22) | (0.33) | (0.26) | (0.38) | (0.40) | (0.49) | (0.54) | (0.59) |
Free Cash Flow per Share |
0.62 | 0.81 | 0.01 | 0.99 | 0.81 | 0.94 | 0.66 | 1.23 | 1.80 | 2.47 |
Cash per Share |
0.14 | 0.14 | 0.11 | 0.16 | 1.22 | 1.35 | 0.65 | 0.60 | 0.28 | 1.33 |
Shareholders Equity per Share |
4.96 | 5.12 | 6.32 | 9.97 | 10.82 | 11.69 | 12.28 | 13.44 | 14.95 | 16.53 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.96 | 5.12 | 6.32 | 9.97 | 10.82 | 11.69 | 12.28 | 13.44 | 14.95 | 16.53 |
Free Cash Flow |
835.00 | 1,107.00 | 8.00 | 1,382.00 | 1,144.00 | 1,330.00 | 950.00 | 1,792.00 | 2,645.00 | 3,658.00 |
Working Capital |
(348.00) | (1,832.00) | (1,257.00) | (167.00) | 3,013.00 | 2,043.00 | 1,957.00 | 1,581.00 | 521.00 | 3,355.00 |
Capital Expenditures |
(347.00) | (319.00) | (302.00) | (454.00) | (364.00) | (540.00) | (576.00) | (711.00) | (790.00) | (876.00) |
Net Current Asset Value |
(8,124.00) | (8,208.00) | (8,270.00) | (11,989.00) | (8,757.00) | (9,290.00) | (9,136.00) | (9,092.00) | (10,472.00) | (10,407.00) |
EV/EBIT |
78.28 | 31.18 | 37.00 | 47.93 | 0.00 | 56.39 | 44.82 | 39.38 | 54.42 | 41.70 |
Capex to Sales |
0.04 | 0.04 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 |
Price to Operating Income |
66.45 | 26.95 | 32.41 | 41.48 | 0.00 | 50.43 | 39.96 | 35.87 | 50.45 | 39.08 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.51 | 0.50 | 0.52 | 0.54 | 0.79 | 0.65 | 0.52 | 0.44 | 0.50 | 0.35 |
Cash ROIC |
6.73% | 8.64% | 0.05% | 5.73% | 4.37% | 4.82% | 3.46% | 6.08% | 7.98% | 9.66% |
Accounts Receivable Turnover |
6.11 | 5.99 | 6.23 | 6.25 | 5.90 | 7.19 | 6.77 | 6.78 | 7.00 | 7.32 |
Accounts Payable Turnover |
7.39 | 5.31 | 6.40 | 6.99 | 6.57 | 5.68 | 4.78 | 4.82 | 5.53 | 5.91 |
Inventory Turnover |
2.46 | 2.55 | 2.51 | 2.27 | 2.37 | 2.51 | 2.28 | 2.00 | 1.99 | 2.16 |
Average Days of Payables |
67.31 | 74.60 | 45.28 | 63.49 | 54.04 | 78.09 | 79.53 | 79.13 | 66.65 | 67.12 |
Days of Inventory on Hand |
143.80 | 151.74 | 151.29 | 184.96 | 142.31 | 158.35 | 172.26 | 208.67 | 195.10 | 172.67 |
Average Receivables |
1,373.50 | 1,510.00 | 1,578.00 | 1,718.00 | 1,679.50 | 1,654.50 | 1,874.00 | 2,099.00 | 2,393.00 | 2,742.00 |
Average Payables |
328.00 | 488.50 | 439.50 | 445.50 | 527.50 | 653.50 | 828.00 | 902.00 | 951.00 | 1,052.00 |
Average Inventory |
985.50 | 1,016.50 | 1,122.00 | 1,372.50 | 1,465.00 | 1,480.50 | 1,738.50 | 2,175.50 | 2,647.00 | 2,876.50 |
Average Assets |
18,114.50 | 18,569.00 | 20,020.50 | 25,782.00 | 30,671.00 | 31,503.00 | 32,349.00 | 33,802.50 | 37,265.50 | 41,534.00 |
Average Common Equity |
6,526.50 | 6,872.00 | 7,868.00 | 11,301.00 | 14,602.00 | 15,975.00 | 17,098.50 | 18,551.50 | 20,766.00 | 23,237.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026